New Study Confirms Safety of Ayurvedic Formulations for Migraine Treatment

Mumbai, July 25, 2025 – A groundbreaking study published in the International Journal of Toxicological and Pharmacological Research has confirmed the safety of a unique combination of five classical Ayurvedic formulations (AYFs) used for the prophylactic treatment of migraines. Conducted by researchers from Ipec Traditional Remedies Pvt. Ltd., Bombay College of Pharmacy, and Ipec Laboratories Ltd., the study evaluated the acute and sub-acute toxicity of these formulations in animal models, providing promising insights into their safety profile.
The Ayurvedic Treatment Protocol (AYTP) comprises Narikela Lavana, Sootshekhar Rasa, Sitopladi Churna, Rason Vati, and Godanti Mishran, combined with dietary and lifestyle modifications. 

These formulations, rooted in India’s 5,000-year-old Ayurvedic tradition, have shown encouraging results in managing migraines, a chronic condition affecting millions worldwide. The study aimed to address concerns about the safety, efficacy, and potential toxicity of these herbal-mineral combinations, which are often scrutinized due to their complex manufacturing processes.

Following OECD guidelines, the research involved acute and sub-acute toxicity studies on Sprague Dawley rats and Swiss Albino mice. The formulations were administered in doses ranging from 1.47 to 7.34 g/kg, with the highest dose being 30 times the recommended human dose of 7.3 g/day. The animals underwent comprehensive evaluations, including hematological, biochemical, necropsy, and histopathological analyses.

The results were highly encouraging: no significant toxic effects were observed across the tested groups. Hematological and biochemical parameters, such as hemoglobin, white blood cell counts, and liver enzyme levels, showed no notable deviations from the control groups. However, a slight decrease in reticulocytes was noted in the satellite high-dose group, which warrants further investigation. Mortality observed in the high-dose group was attributed to the elevated levels of Narkela Lavana, but no other adverse effects were reported.

Dr. Prakash Vaidya Balendu, the lead researcher, emphasized the significance of these findings: “This study validates the safety of our Ayurvedic formulations for migraine management, addressing public concerns about the use of herbo-mineral remedies. While these results are promising, we recommend further chronic toxicity studies to ensure long-term safety.”

The growing popularity of complementary and alternative medicine (CAM) for chronic conditions like migraines underscores the need for such research. The study highlights Ayurveda’s potential as a safe and effective option for migraine sufferers, paving the way for broader acceptance and integration into mainstream healthcare. For more details, contact VCPC Researh Foundation at 9758509973